News Category: General News

SAN DIEGO –(BUSINESS WIRE)–Sep. 22, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 8, 2023 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,749

SAN DIEGO –(BUSINESS WIRE)–Sep. 19, 2023– Acadia Pharmaceuticals Inc . (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate

SAN DIEGO –(BUSINESS WIRE)–Aug. 30, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi’s 18 th Annual BioPharma Conference Date: Wednesday, September 6, 2023 Location: Boston, MA Format: 1×1 Meetings

SAN DIEGO –(BUSINESS WIRE)–Aug. 14, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 1, 2023 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 40,612 shares

SAN DIEGO –(BUSINESS WIRE)–Aug. 1, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 18, 2023 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 19,903 shares of

SAN DIEGO –(BUSINESS WIRE)–Jul. 24, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023 . Dr. Oliver will oversee all business development functions and will serve as a

Company to host conference call and webcast on Wednesday, August 2, 2023 , at 4:30 p.m. Eastern Time SAN DIEGO –(BUSINESS WIRE)–Jul. 19, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 2, 2023 , after the

— Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first and only drug approved for the treatment of Rett syndrome — Acadia provides DAYBUE launch update and announces second quarter preliminary net sales and guidance for third quarter — Company to host

SAN DIEGO –(BUSINESS WIRE)–Jun. 26, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 13, 2023 , the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 153,615 shares

— Acadia acquired Levo Therapeutics and worldwide rights to ACP-101 in June 2022 — ACP-101 (intranasal carbetocin) is a selective oxytocin-receptor agonist for the treatment of hyperphagia in Prader-Willi syndrome — Company recently completed a meeting with the FDA and plans to initiate a Phase